Abivax (ABVX) Beginning Cash Balance (2024 - 2025)
Abivax's (ABVX) quarterly Beginning Cash Balance came in at $151.7 million in Q1 2025, down 44.57% year-on-year from $273.7 million in Q1 2024, and down 44.57% quarter-over-quarter from $273.7 million in Q1 2024.
Abivax (ABVX) Beginning Cash Balance (2024 - 2025) Analysis & Trends
Abivax's Beginning Cash Balance history runs 2 years deep, the most recent figure standing at $151.7 million for Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Abivax | 9.98 Bn | 9.98 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 151.70 Mn |
| Mar 31, 2025 | 151.70 Mn |
| Mar 31, 2024 | 273.70 Mn |
| Mar 31, 2024 | 273.70 Mn |